(3) has ushered in a new era of immunosuppressive therapy. CsA has had a major impact on our understanding and ability to selectively control the immune response.
Since 1983 more than 6000 papers dealing with CsA have been published, with the current rate estimated at 1500 papers per year (4). The early promise of CsA as an agent that promotes the suppression of graft rejection has been realized in some significant ways. The overall improvement in graft survival for renal (5) , heart (6), and liver transplants (7) ; the reduction in the number of life-threatening infections (8, 9) ; and the reported shortening of hospital stay (8) are benefits attributed to the use of CsA. Current immunosuppressive drug regimens used in many transplant centers are based on "triple drug therapy"-CsA, azathioprine, and prednisone. Some centers have maintained the strategy of using CsA and prednisone and, where possible, eliminating steroid from the regimen. The goal of eliminating steroid from the regimen in patients for at least one year and as long as five years has been achieved in low-responder living-related-donor kidney graft recipients with apparent success (10, 11) . It is no surprise that the number of solid-organ transplant procedures performed annually has doubled since the introduction of CsA into clinical practice in December
1983. An extensive set of clinical trials are under way in attempts to take advantage of CsA's ability to The recent report of the NACB/AACC task force on CsA monitoring extensively described critical issues that had arisen on this topic (13) . Although the latter will be referred to in appropriate places, this review will focus on (a) 
Cellular Growth Regulation Mediated by C8A
CsA exerts a spectrum of cellular actions and striking effects on the growth of several different types of cells. (18) , in human T cell acute lymphatic leukemia cells (19) , and in a human small cell lung cancer cell line in vitro (20) . The mechanism of this effect, as well as its possible clinical application, will undoubtedly be the subject of future investigations. A paradoxical effect of CsA is its stimulation of IgE production and T helper cell priming in response to standard antigenic challenges in several strains of mice (21) . The possible mechanisms for this effect of CsA are described in reference 21.
Studies in psoriasis patients have shown that CsA administration eliminated psoriatic lesions partially or completely in most of the patients in an initial study (22) (23) (24) . More extensive trials are under way. The cellular mechanisms that lead to psoriasis are a subject of vigorous debate (24) . Does the hyperproliferation of epidermis result from a primary defect in keratinocyte growth regulation, or is it secondary to dermal influences (24) ? Are T cells involved in the growth regulation abnormality?
These are unanswered questions and, therefore, we do not yet know the cellular site(s) of action of CsA in this disease. But CsA definitely exerts a profound inhibition of the abnormal proliferation of cells that cause psoriasis.
Mechanism of inhIbItIon of T-CeIi Activation and Proliferation by CsA

Cellular Events
The rejection of transplanted tissue and graft-vs-host disease are complex immune processes that involve the communication and interaction of a number of lymphocyte cell populations that, in turn, produce powerful and specific immunologic rejection mechanisms (25) . The mixed lymphocyte reaction, in which cytotoxic T lymphocytes are generated and lymphokines are produced, is a widely used in vitro model of this process. In the mixed lymphocyte reaction, CsA inhibits early events in the activation and In this same study they also evaluated the effect of CsA on gene activation elicited by concanavalin A or IL2, in a cloned murine T cell (L2). The CsA specifically blocked the production of messenger RNAs for the c-myc and p53 proto-oncogenes when induced by concanavalin A but not when they were induced by 1L2 (28) . Apparently, more than one pathway controls the expression of a particular gene in T cells, and CsA selectively blocks only certain regulatory pathways of gene expression in these cells (28) .
In another study, evidence was presented that more than 62 genes were activated in the early stages of T-cell activation by phytohemagglutinin and phorbol myristate acetate in the presence of cycloheximide (31). Using northern blots and nm-on transcription techniques, investigators concluded that CsA inhibited the expression of about 50% of the activated genes, with no apparent effect on the In vitro studies with phorbol esters (which bind to and directly activate protein kinase c) and calcium ionophores in place of antigens or mitogenic lectins have led to a two-signal model for T-cell activation wherein the combination of increased free Ca2 and activation of protein kinase c appear to be required for the full activation of T cells (33, 34) . Most reports indicate that CsA blocks events (including gene expression) induced by calcium ionophores but not those stimulated by phorbol esters (25) . These and other studies indicate that CsA interferes with only some of the pathways that stimulate gene expression in T cells.
In considering how CsA inhibits T-cell activation, additional information at the molecular level needs to be taken activities. Other cytosolic proteins (Mr up to 200 000) that bind CsA have been described (36, 37) , although thus far cyclophilin is quantitatively much more significant.
If cyclophilin is involved in the activation of genes in T cells, one possible way CsA could block activation would be via a direct inhibitory effect on the putative protein kinase activity of cyclophilin.
Another hypothesis (32) is that cyclophilin provides a "sink" that makes it possible to achieve sufficiently high concentrations of CsA within cells to effectively inhibit activation at some as-yet-to-be-defined intracellular site(s).
One such intracellular site is activated calmodulin. Thus, another suggested molecular mechanism by which CsA could inhibit T-cell activation is the inhibition of calmoduun activation through one of the two triggering pathways described above (25) . Other investigators (36) have discounted this hypothesis because of not being able to demonstrate in vitro binding to calmodulin, whereas such binding has been demonstrated for cyclophilin in numerous laboratories. Possibly CsA causes inhibition of activated calmodulin by an as-yet-undiscovered indirect process.
A third possibility is that CsA interacts with putative T-cell-specific transcription factors, such as that which activates the IL2 gene (38) , in such a way that the expression of certain genes is inhibited during the activation stage of T cells in the MLR (29, 38) . What the putative T-cell-specific transcription factors are, and how CsA could modulate them, are subjects for future investigation. A fourth possible mechanism is the inhibition of peptidylprolyl cis-trans isomerase, an enzyme recently shown (39, 40) to be identical in structure to cyclophilin.
CsA inhibits
its catalytic activity for the cis-trans isomerization of proline imidic peptide bonds, a reaction thought to be essential for protein folding during protein synthesis in the cell. Fischer et al. (40) postulate that in T cells this catalytic activity is necessary for the production of key proteins, in their fully active conformations, required for T-cell activation. Clearly much work remains to be done to elucidate the intricate mechanisms responsible for T-cell activation and how CsA inhibits that process.
Pharmacokinetic Variability of CsA
The extensive inter-and intrapatient variations in steady-state trough CsA concentrations in blood for a given 
No change
No change weight-adjusted dose of the drug are well known (13, 41) .
The extent and causes of variability in the absorption, distribution, metabolism, and elimination of CsA in transplant patients of all types were recently reviewed in detail in the report of the NACB/AACC task force on CsA monitoring (13). These will not be discussed again here, but the causes of the clinically most important changes in blood concentrations ofCsA at trough are summarized in Table 1 . A valuable recommendation that provides the ability to individualize an optimal dosage of CsA on the first day of therapy is performance of pharmacokinetic studies before transplant surgery (42, 43) . By performing pro-treatment oral and intravenous pharmacokinetic studies of the parent drug CsA over consecutive 24-h periods, possible problems such as poor absorption and (or) rapid or slow clearance can be identified and the initial doses adjusted accordingly. This approach provides the most accurate way to reach target blood concentrations in the shortest possible time. In a recent evaluation of pre-transplant pharmocokinetics in heart-lung transplant candidates with cystic fibrosis (44), we used a monoclonal specific 3H-RIA method to identify poor absorption (ranging from 7% to 17%) in each of the six patients evaluated. In this study we uncovered a sub-population of patients with a pre-disposition to poor absorption, whose initial oral dosing in conjunction with transplant surgery must be increased accordingly.
In a recent study of the effect of time on CsA pharmacokinetics, the dose-adjusted trough concentration of CsA (HPLC method) in blood of renal-transplant patients at three months post-transplant was almost double the value obtained after one week (0.23 ± 0.13 vs 0.12 ± 0.06 ng/mL per milligram of CsA dose) (45) . Further study will be required to determine whether increasing bioavailability of CsA or increasing hematocrit and plasma lipids and proteins produce the increase in dose-adjusted trough concentrations of CsA (45) .
The circadian influence on CsA pharmacokinetics can be significant and is another source of intra-and interpatient variation (46) . Eighteen of 24 paired amlpm 12-h trough concentrations of CsA (determined by HPLC) were lower by an average of 44.7% after a morning CsA dose than the average trough concentrations after an evening dose (46) . These data emphasize the importance of measuring trough concentrations at a consistent time of day. The authors suggest that, in patients in whom the magnitude of these differences is large, optimizing immunosuppressive therapy with CsA might require lowering the evening dose, or raising the morning dose, or both (46, 47 Experience thus far has convinced most transplant centers of the need for periodic checks of CsA concentrations after the patient leaves the hospital as a measure of compliance and because of the potential for clinically significant drug interactions if concomitant drug therapy is altered (13 This is all the more critical in view of the trend toward using lower dosages of CsA in transplant patients (48 (48) . Many studies in which any one of these methods was used to measure CsA or CsA plus metabolites in either serum, plasma, or whole blood have been described in the literature (13) . These early reports provided some basic understanding about the use of CsA measurements in attempting to individualize the CsA dose. The use of virtually all possible combinations of methods and sample matrices in these studies produced a bewildering array of concentrations and made inter-center comparison of CsA monitoring a difficult, if not impossible, task. In the same sample matrix, nonspecific methods (i.e., those that measure parent drug plus metabolites) can produce concentration values as much as 51-fold higher than the respective concentrations of the parent drug (53) .
Selection of Specimen
The recommendation to measure the parent drug in whole blood by specific HPLC or monoclonal immunoassay methods (13) is based not only on the value of making studies from different centers more readily interpretable but also on (a) the fact that the parent drug possesses potent concentration-dependent immunosuppressive activity and nephrotoxicity and (b) the value of knowing what is being measured. As discussed below, the immunosuppressive activity of CsA metabolites is a hotly debated question, although most investigators agree that some metabolites, especially metabolite 17, possess at least a small degree of immunosuppressive activity. The few published studies of metabolite nephrotoxicity indicate little if any toxicity, as compared with the parent compound. When using a nonspecific immunoassay alone, it is virtually impossible to know how much parent drug and what concentrations of individual CsA metabolites are reported in each measurement.
Further compounding this problem is the observation that the degree of cross-reactivity of three different polyclonal immunoassays towards specific CsA metabolites varies considerably ( (57) . Using this antibody, Sandoz has developed a 3H-RIA specific for CsA. Incstar Corporation has also produced an RLA kit, using the same monoclonal antibody but with an iodinated CsA ligand that provides concentrations for whole-blood samples comparable with HPLC-measured values (58) . El. du Pont de Nemours and Co. Inc. and Syva Co. are also developing immunoassays with the Sandoz specific monoclonal antibody. These developments will make possible the widespread use of specific measurements of the parent drug CsA in therapeutic monitoring and transplantation programs throughout the world. Indeed, the recent report of the United Kingdom CsA Quality Assessment Scheme (59) noted a trend toward the use of specific methods for CsA measurement.
In July 1987, 26% of reported results were for specific methods; by August 1988, the percentage had risen to 57% (59) . Although these developments suggest that interlaboratory comparisons of CsA monitoring data will be very much facilitated in the near future, a note of caution is appropriate: initial results from the UK Quality Assessment Scheme indicate that further refinements in methodology will be required to improve the analytical performance of the specific methods (59, 60) .
CsA Nephrotoxicity
Nephrotoxicity is generally considered to be the clinically most important adverse effect of CsA (61) . Doseresponse studies in rat models have shown that CsA nephrotoxicity is expressed acutely as a dose-dependent increase in renal vascular resistance, a decrease in renal blood flow, and a decrease in glomerular filtration rate (62) . These early changes are functional, fully reversible when the drug is withdrawn, and involve no major permanent structural changes (63, 64) . When administered chronically to rats in high doses, 25 mg/kg intraperitoneally daily for 28 consecutive days, significant functional and structural changes can be produced (65) . The glomerular filtration rate decreased to 30% of the control value and there was a consistent appearance of several structural changes, including patchy interstitial fibrosis, tubular atrophy, interstitial inflammation, and marked hypertrophy and hyperplasia of the juxtaglomerular apparatus (65) . The CsA concentration in blood 24 h after the last CsA dose averaged 4712 .tg/L, more than 20-fold higher than the usual trough concentrations obtained in transplant patients. In humans, as in rats, it is generally agreed that the characteristic hemodynamic effects of CsA are an increased renal vascular resistance, a decreased renal blood flow, and a consequent decrease in glomerular filtration rate (66) . There is also a consensus that these acute effects are renal vasoconstriction, and (or) a direct effect of CsA on the glomerular capillary, which changes the ultrafiltration characteristics of this capillary system. Chronic CsA nephrotoxicity has been observed in some transplant patients (67) . Minimizing acute nephrotoxicity by maintaining whole-blood concentrations of CsA within a narrow range of concentration reduces the chance of developing acute nephrotoxicity, which, in turn, should reduce the possible development of chronic nephrotoxicity (13, 53) . Curtis and Laskow suggest that pharmacological studies aimed at reversing CsA-induced vasoconstriction will help to further elucidate the mechanism of nephrotoxicity and provide the means for controlling it clinically (66) .
It is likely that certain factors, including endotoxm (68), renal ischemic injury (69), aminoglycoside antibiotics (70), other nephrotoxic agents such as amphotericin B, preexisting kidney disease in non-renal-transplant patients, and possibly other unidentified influences, will predispose patients to the nephrotoxic effects of CsA. Patients whose kidneys are impaired by any of these factors may be at greater risk than others for developing nephrotoxicity, even when their CsA concentrations in whole blood are within the target range (68).
Immunosuppressive and Toxic Activity of GsA Metabolites
CsA is extensively metabolized by the liver cytochrome p450 complex. blood, bile, and urine with use of a gradient HPLC method (71) . Although the structures of the first 12 of these have been elucidated in mass spectroscopy and nuclear magnetic resonance studies (72) (73) (74) , the structures of the others remain to be determined.
The structurally characterized metabolites are produced by metabolic reactions involving hydroxylation, demethylation, oxidation, and cyclization of CsA (Figure 1 ). HPLC methods have been developed for measuring CsA metabolites in biological fluids and tissues (75) (76) (77) (78) (79) (80) .
Considerable efforts have been made to determine whether any of the CsA metabolites are immunosuppressive. Several investigators, using in vitro tests of immunosuppression, have reported little or no immunosuppressive activity for metabolites (74, (81) (82) (83) . Others have reported significant activity for a few metabolites, especially metabolite 17 (84) (85) (86) , either by itself (84, 85) or synergistically with CsA in a clone of T lymphocytes cultured from heart-tissue biopsy obtained during a rejection episode (86) 
an animal transplant model, which would avoid potential biases that might occur in in vitro model systems and to examine the ability of the metabolites, in comparison with CsA, to prevent rejection of the transplanted tissue. Now that sufficient quantities of some metabolites are being purified from human bile, it should be possible for some investigators to test for in vivo immunosuppressive activity of CsA metabolites.
Indeed, Wong and collaborators, using rat small intestine as a transplant model, are comparing metabolite immunosuppressive activity with that of CsA (87) . Studies such as these should presumably lead to an answer to the question: do any CsA metabolites exert a clinically significant immunosuppressive effect? Are any CsA metabolites nephrotoxic? This question has been tested directly in two published studies thus far (88, 89) . Ryffel et al. (88) , in their spontaneously hypertensive rat model for CsA nephrotoxicity, evaluated the toxic potential of purified metabolite 17 and of a mixture of CsA metabolites extracted from transplant patients' bile. This group reported that, after four weeks of daily intraperitoneal administration of metabolite 17 or the biliary metabolite mixture, 10 mg/kg, neither functional nor morphologic changes were observed (88) . In contrast, the same dosage regimen of CsA in the standard olive-oil vehicle produced a substantial decrease in glomerular filtration rate and morphologic alterations:
exudative arteriolopathy and regenerative renal tubular changes (88) . The acknowledged limitation in these detailed direct studies of the toxicity of metabolite 17 is the lack of specific measurement of the metabolite in the blood or tissues of the rats. Because of the striking intra-and interpatient variability in the absorbance and clearance of CsA and its narrow therapeutic window, most centers have adopted regular monitoring of CsA concentrations in blood (serum or plasma) to guide dosage. The early experience regarding the utility of monitoring CsA concentrations in most studies was that there was a degree of correlation between the drug's concentration and the occurrence of nephrotoxicity (CsA concentrations relatively high) or transplant rejection (CsA concentrations relatively low) (48) . In several ongoing or published (9, 91, 92) studies, the dosage of GsA was adjusted to maintain whole-blood concentrations at trough within a narrow range to reduce the risks of rejection and nephrotoxicity.
In the CsA era of immunosuppressive therapy, patient and graft survival rates are higher than ever before. The goal of transplant centers is to further improve the clinical outcome for each transplant patient, with the ultimate goal being earlier detection and control of acute rejection and chronic nephrotoxicity.
In my opinion, the regular adjustment of CsA dosage to achieve and maintain whole-blood concentrations within a narrow range at trough and possibly to allow a pharmacokinetic evaluation of each patient can contribute to a further improvement of clinical outcome. Other improvements such as the development of a simple and reliable method for the early detection of acute rejection could provide additional help.
Two recent studies document clinical outcomes for renaltransplant patients whose whole-blood concentrations of the parent drug, measured at trough by a specific method (HPLC), were maintained within narrow ranges. In the first of these (9) the clinical characteristics for 39 patients receiving CsA plus prednisone therapy, and followed for 15 to 18 months after transplant surgery, were as follows: 13 received kidneys from living relatives, 26 from cadaver donors; for 27 patients the kidney transplant was their first, and for 12 (31%) it was their second or third. The following clinical outcomes were obtained: 17 (44%) encountered at least one episode of acute rejection within the first year after transplant surgery, with 70% of these occurring within the first four months. Fourteen of these 17 patients had a whole-blood concentration of CsA at trough of <125 ,ug/L at the time of the episode; the remaining three (18%) had concentrations at the lower end of the target range. Only two of the 39 patients had episodes of CsA-related nephrotoxicity, and in both the whole-blood concentrations of CsA at trough had been at the high end or above the target ranges, 262 and 361 g/L, at the time of the nephrotoxic episodes. Moyer et al. (9) made no mention of whether they detected either chronic rejection or chronic nephrotoxicity in these 39 patients. For the duration of the study, serial measurements of serum creatinine remained stable, with an average value of 17.9 mgIL at 15-18 months post-transplant. lothalamate clearances were performed on the majority of these patients and showed no deterioration in the mean end-of-study value (46.6 mL/min per 1.73 m2) compared with an initial mean value of 41.9.
In the second study (91) whole-blood trough concentrations of CsA were also maintained within a narrow range. Whenever they were found to be outside the range, dosage was adjusted to bring the concentration back within the range, regardless of whether clinical events such as nephrotoxicity or rejection were occurring. In this study Uchida et al. (91) followed 127 adult renal-transplant recipients (76 living related donors, 51 cadaver donors) for up to four years. Concentrations of CsA in whole blood were measured by HPLC in specimens obtained just before the morning dose. Dosage adjustments were made to keep trough blood concentrations of CsA within 200 (±20) gfL for the first three months after transplant surgery for the recipients of kidneys from a living relative. After three months, the dosage for these patients was reduced to achieve blood concentrations within 100 (±20) pgfL. For the recipients of cadaver kidneys the target trough blood concentration of CsA was 100 (±20) ug/L in the immediate post-transplant period as long as the serum creatinine values were 30 mgIL (91) . If serum creatinine values dropped to <30 mg/L, the CsA dosage was adjusted to achieve 200 (±20) ig/L trough blood concentrations for the first three months post-transplant, then reduced to maintain trough concentrations within 100 (±20) jig/L. These concentrations were determined three times per week during hospitalization and at every outpatient clinic visit thereafter.
In this study, when serum creatinine concentrations increased by more than 25% above the baseline value with no evidence of rejection, the CsA dosage was decreased (91) . If rejection was suspected, a graft biopsy was performed. When CsA concentrations were outside the target ranges in the absence of rejection or toxicity, the dosage was adjusted to bring them back within the appropriate range.
The clinical outcome for patients in this study was as follows. Acute rejection episodes occurred in 46 (36.2%) of the 127 patients: for the 37 patients who experienced acute rejection within the first 90 days post-transplant, CsA blood concentrations were within the target range; for the nine who experienced acute rejection after 90 post-transplant days, concentrations in blood were below the lower limit of the target range, 80 tg/L. A total of 17 patients (13.4%)-11 treated for acute rejection and six who had no acute rejection at all-developed chronic rejection. Five patients (3.9%) developed mild chronic renal dysfunction, presumed to be nephrotoxicity because there was no evidence of active rejection episodes on biopsy examination. There was no evidence in any of these patients of progressive deterioration of renal function. No indication was made in this report of the number of patients who had prior kidney transplants and who, therefore, would be at greater Presence of toxicity Heart risk for rejection.
Based on these studies, the target ranges summarized in Table 3 are recommended for monitoring the concentration of the parent drug CsA in whole-blood samples obtained at trough from renal-transplant patients. Further long-term prospective studies to confirm the proposed therapeutic drug monitoring guidelines are needed. Included in the final report of such a study should be the incidence of acute and chronic rejection, acute and chronic nephrotoxicity, and, of course, patient-and graft-survival data. The proposed lower concentration limit of 150 ug/L for minimizing renal-graft rejection within the first three months after surgery appears to be substantiated by the recent study of Holt et al. (92) . These investigators, using CsA concentration values measured in two to six blood specimens collected 8-10 h after the last drug dose within the seven days preceding diagnosis, found that 14 of 32 rejection episodes were associated with median CsA concentrations of <200 tgfL. This cutoff value for the parent drug in whole-blood specimens collected 8-10 h after the last dose is roughly equivalent to 150 pgfL in specimens collected 11-12 h after the last dose (D . Holt, personal communication) .
Investigations of the relationship between CsA concentrations and clinical events in heart, liver, and other transplant patient populations are under way. However, there are no definitive published studies on this subject. For liver-transplant patients Wonigeit (93) has discussed provisional guidelines for CsA whole-blood concentrations similar to those discussed above for renal-transplant patients: >200 .&gfL in the first few months post-transplant and 100 to 200 p.g/L thereafter. Should nephrotoxicity, neurotoxicity, or hypertension attributable to CsA develop in liver-transplant patients in the early post-transplant period, the Mayo Clinic liver-transplant team recommends lower GsA dosage to achieve target whole-blood concentrations of CsA at trough of 80 to 120 pg/L and adding azathioprine to the immunosuppression regimens (94) . The latter group otherwise uses a target CsA concentration range of 250 to 350 g/L for the first few months after surgery, which is similar to that suggested by Wonigeit. A suggested set of target ranges for heart-transplant patients follows the same overall concept of lowering the blood concentrations upon stabilization of graft function (T. Schroeder, personal communication; see Table 3 for details).
Another aspect of monitoring GsA concentrations in whole blood, which merits consideration, is the use of pharmacokinetic studies to guide GsA dosage. Recent reports suggest that the use of pharmacokinetic evaluations of GsA in renal-transplant patients can provide more predictive information about the likelihood of subsequent rejection (95, 96) . This area of CsA monitoring is deserving of further evaluation to establish the potential benefits vs monitoring trough concentration, in terms of the respective costs involved.
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